Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/06/2005USRE38913 in endoprosthesis practice by injections to remedy defects in humans which are due to traumatic, congenital or age distorsions of the shape and dimensions or due to loss of form stability of some organs consisting soft tissues
12/06/2005USRE38912 for treating a number of complaints, particularly respiratory diseases
12/06/2005US6972462 Compact high voltage ESD protection diode
12/06/2005US6972343 such as N,N'-diformyl-N,N'-di[1-methyl-2-S-thiobenzoyl-4-methoxybut-1-enyl]-1,12-diaminododecane; for treatment of malaria
12/06/2005US6972341 Prodrugs of GABA analogs, compositions and uses thereof
12/06/2005US6972335 useful as highly specific, non-toxic anticancer therapeutics and provides methods of inhibiting multidrug resistant cells
12/06/2005US6972328 can comprise DNA, RNA, PNA, or any combination or chimera thereof
12/06/2005US6972300 Compounds and compositions for delivering active agents
12/06/2005US6972299 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
12/06/2005US6972298 Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor
12/06/2005US6972297 2-Hydroxy-mutilin carbamate derivatives for antibacterial use
12/06/2005US6972296 Antichoelsterol agents; cardiovascular disorders; antihistamines; multiple sclerosis; antihistamines
12/06/2005US6972295 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis
12/06/2005US6972294 Compounds, their preparation and use
12/06/2005US6972292 Exhibit a higher degree of selectivity in killing cancer cells.
12/06/2005US6972291 Method for reducing food intake
12/06/2005US6972290 Piperazine derivatives and their use as anti-inflammatory agents
12/06/2005US6972289 dehydrodiketopiperazines such as dehydrophenylahistin used as antitumor agents; dipeptides
12/06/2005US6972288 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
12/06/2005US6972287 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
12/06/2005US6972286 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle
12/06/2005US6972284 Deacetylation chitin with base
12/06/2005US6972283 Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
12/06/2005US6972179 RRP sequences and knockout mice and uses thereof
12/06/2005US6972175 Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods
12/06/2005US6972171 mixing polynucleotides with folic acid, hormones, peptides, glycoproteins, lipids or phosphatides to form nucleotides used as drugs; genetic engineering; gene expression
12/06/2005CA2354606C Azabicycloalkane derivatives and therapeutic uses thereof
12/06/2005CA2352528C Phosphatidyl-l-serine and phosphatidic acid composition as anti-depressant, stress suppressor and mood improver
12/06/2005CA2349338C Novel macrolide antibiotics
12/06/2005CA2347512C Adenine derivatives
12/06/2005CA2331873C Fumagillol derivatives and processes for preparing the same
12/06/2005CA2325282C Use of apo b secretion/mtp inhibitors
12/06/2005CA2303537C Solid oral dosage form comprising a combination of metformin and glibenclamide
12/06/2005CA2303244C Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
12/06/2005CA2303177C Taste masked pharmaceutical compositions
12/06/2005CA2289599C Substituted heterocyclic compounds, method for preparing and compositions containing same
12/06/2005CA2284774C Theobromine antitussive compositions
12/06/2005CA2272745C 2-alkyl-19-nor-vitamin d compounds
12/06/2005CA2268866C Substituted arylalkylamines as neurokinin antagonists
12/06/2005CA2244907C Formulated product
12/06/2005CA2235942C Tricyclic erythromycin derivatives
12/06/2005CA2235840C Phenylethanolamine compounds useful as .beta.3 agonist, process for producing the same, and intermediates in the production of the same
12/06/2005CA2233975C Succinimide and maleimide cytokine inhibitors
12/06/2005CA2233558C Method and pharmaceutical composition for regulating lipid concentration
12/06/2005CA2226488C Polysaccharide gel composition
12/06/2005CA2206787C 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same
12/06/2005CA2188529C Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
12/06/2005CA2180846C Method of treating disorders of the eye
12/06/2005CA2173257C Novel (r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1-benzopyranes
12/06/2005CA2163115C N-substituted beta-aryl- and beta-heteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
12/06/2005CA2148593C Use of piperazine derivatives for the treatment of cognitive disorders
12/06/2005CA2129527C Pharmaceutical composition usable as an analgesic, comprising (r)-(benzoyl-3-phenyl)-2-propionic acid
12/06/2005CA2096528C Retroviral protease inhibitors
12/06/2005CA2095708C Novel n-aralkyl- and n-heteroaralkyl-aminoalkanephosphinic acids
12/06/2005CA2079831C Biodegradable polymer composition
12/06/2005CA2061061C Blockage of coenzyme a-independent transacylase activity as a method to inhibit lipid mediator production
12/05/2005WO2005116054A1 Process for preparing acyclic hcv protease inhibitors
12/05/2005CA2568008A1 Process for preparing acyclic hcv protease inhibitors
12/04/2005CA2568914A1 Therapeutic agents, and methods of making and using the same
12/03/2005CA2529613A1 Agent for repairing corneal sensitivity containing amide compound
12/02/2005CA2509077A1 Water-based compositions comprising a polyethylene glycol-based solubilizing agent and a taxane useful in the treatment of coronary artery disease
12/01/2005WO2005114180A2 Functional ghs-r antagonists
12/01/2005WO2005113833A2 Polymorphism in tryptophan hydroxylase-2 controls brain serotonin synthesis
12/01/2005WO2005113763A1 Inhibition of erk-phosphorylation
12/01/2005WO2005113586A2 Disease-associated proteins
12/01/2005WO2005113569A1 Novel 3-triazolyl-galactoside inhibitors of galectins
12/01/2005WO2005113568A1 Novel galactoside inhibitors of galectins
12/01/2005WO2005113562A1 Hiv integrase inhibitors: cyclic pyrimidinone compounds
12/01/2005WO2005113561A1 Cyclicsulfonate pyrrole indolinones as kinase inhibitors
12/01/2005WO2005113557A1 Method for the catalytic production of hydrocodone and hydromorphone
12/01/2005WO2005113556A1 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
12/01/2005WO2005113554A2 Method of preparing 3-phenyl-2-[9h-purin-6-ylamino)-methyl]-3h-quinazolin-4-one and substituted and related compounds
12/01/2005WO2005113551A1 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
12/01/2005WO2005113550A1 Aminopyrimidine derivative and medicinal use thereof
12/01/2005WO2005113548A1 Thiophene heteroaryl amines
12/01/2005WO2005113546A1 Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
12/01/2005WO2005113541A1 Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
12/01/2005WO2005113540A1 Isoquinoline compound and pharmaceutical use thereof
12/01/2005WO2005113537A2 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
12/01/2005WO2005113535A2 Pyrazinylmethyl lactam derivatives
12/01/2005WO2005113534A2 Cxcr1 and cxcr2 chemokine antagonists
12/01/2005WO2005113532A1 Chromene-derivatives with anti-tubulin and vascular targeting activity
12/01/2005WO2005113527A1 Tetrahydronaphthyl- piperazines as 5-ht1b antagonists, inverse agonists and partial agonists
12/01/2005WO2005113526A2 Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
12/01/2005WO2005113525A1 N, n’-substituted-1,3-diamino-2-oxopropane derivatives, their pharmaceutical compositions and use
12/01/2005WO2005113523A1 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
12/01/2005WO2005113522A1 Azole carboxamide inhibitors of bacterial type iii protein secretion systems
12/01/2005WO2005113521A1 Process of preparing substituted carbamates and intermediates thereof
12/01/2005WO2005113520A1 Substituted 2,3,5-trifluorphenyl oxazolidinones for use as antibacterial agents
12/01/2005WO2005113517A1 Phosphodiesterase-inhibiting compounds of the 2,3-benzodiazepine type
12/01/2005WO2005113514A2 Substituted pyrimidines as inhibitors of bacterial type iii protein secretion systems
12/01/2005WO2005113511A1 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
12/01/2005WO2005113508A1 Stable crystal of 4-oxoquinoline compound
12/01/2005WO2005113507A1 Substituted quinoline derivatives as mitotic kinesin inhibitors
12/01/2005WO2005113506A1 Compounds and compositions as ppar modulators
12/01/2005WO2005113503A2 Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine
12/01/2005WO2005113501A1 Neurogenic pain control agent composition
12/01/2005WO2005113499A1 Indole compounds
12/01/2005WO2005113497A1 Substituted 5-aminomethyl-1h-pyrrol-2-carbxylic acid amides
12/01/2005WO2005113496A1 Method for producing 1,4-diphenyl azetidinone derivatives
1 ... 4446 4447 4448 4449 4450 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 4461 4462 4463 4464 4465 4466 ... 7860